期刊文献+

以循证医学观点看待口服避孕药的静脉血栓栓塞风险 被引量:6

下载PDF
导出
摘要 口服避孕药的静脉血栓栓塞风险是育龄期妇女和临床医生关注的焦点。本文从循证医学的角度出发,对当前有关口服避孕药的静脉血栓栓塞风险的研究进行分析。结果表明:虽然使用口服避孕药者发生静脉血栓栓塞的相对风险高于未使用者,但其绝对风险仍然较低。由于当前的研究结果受较多的偏倚因素和混杂因素影响,各种口服避孕药诱发静脉血栓栓塞的风险值差异问题,目前尚无肯定的结论。总体而言,使用口服避孕药的收益远大于其危害。临床医生可在确认无口服避孕药的禁忌证后,综合考虑妇女的个体因素再选取适宜的口服避孕药。
出处 《实用妇产科杂志》 CAS CSCD 北大核心 2012年第10期816-819,共4页 Journal of Practical Obstetrics and Gynecology
  • 相关文献

参考文献14

  • 1Reid R, Society of Obstetricians and Gynecologists of Canada. SOGC clinical practice guideline. No. 252, December 2010. Oral contracep?tives and the risk of venous thromboembolism: an update [J]. J Ob?stet Gynecol Can,2010,32( 12) :1192 -1204.
  • 2Jick SS, Hernandez RK. Risk of non-fatalvenous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel , case-control study using United States claims data [] lOL J. BM] , 2011 ,342 :d2151 [2012-1O-D7 J. http://www.bmj.com.
  • 3Parkin L, Sharples K, Hernandez RK, et al. Risk of venous thrombo?embolism in users of oral contraceptives containing drospirenone or levonorgestrel : nested case-control study based on UK General Prac?tice Research Database [] /OL J. BMJ, 2011,342: d2139 [2012- 10-7]. http://www.bmj.com/content.
  • 4Koster T ,Small RA, Rosendaal FR, et al. Oral contraceptives and ve?nous thromboembolism: a quantitative discussion of uncertainties [J J . J InternMed,1995 ,238(1) :31 -37.
  • 5Hennessy S, Berlin JA, Kinman JL, et al. Risk of venous thromboem?bolism from oral contraceptives containing gestodene and desogestre! versus Ievonorgestrel , a metaanalysis and formal sensitivity analysis [J]. Contraception ,2001 ,64(2) :125 -133.
  • 6Ke mmeren JM, Algra A, Grobbee DE. Third generation oral contra?ceptives and risk of venous thrombosis: metaanalysis [Jl. BMJ ,2001, 323 (7305) : 131 -134.
  • 7WU O,Robertson L,Langhoroe P,et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembo?lism : a systematic review. The thrombosis: risk and economic assess?ment of thrombophilia screening ( TREATS) study [J J . Thromb Haem?ost,2005,94(1) :17 -25.
  • 8Martinez F , Ramirez I, Perez-Campos E, et al. Venous and pulmonary thromboembolism and combined hormonal contraceptives. systematic review and meta-analysis [J J . Eur J Contracept Reprod Health Care,' 2011,17( 1):7 -29.
  • 9Manzoli L, De Vito C, Marzuillo C, et al. Oral contraceptives and ve?nous thromboembolism: a systematic review and Meta-analysis [J J . Drug Saf,2012,35(3) :191 -205.
  • 10Lidegaard 0, Lekkegaard E, Svendsen AL, et al. Hormonal contracep- tion and risk of venous thromboembolism: national follow-up study [JI OLl. BMJ ,2009 ,339 :b2890[2012-1O-7] http://www.bmj.com.

同被引文献74

  • 1陈昆陵.氨甲苯酸注射液致过敏性皮疹1例[J].重庆医学,2005,34(10). 被引量:2
  • 2Dinger JC, Heinemann LA, Klihl - Hafaich D. The safety of adrospirenone - containing oral contraceptive : final results from theEuropean Active Survillance study on oral contraceptives based on142 475 women - years of observation[ J]. Contraception,2007,75(5) : 344-354.
  • 3Seeger JD,Lou^ilin J,Eng PM, et al. Risk of thromboembolism inwomen taking Ethinylestradiol/ drospirenone and other oralcontraceptives[ J] . Contraception, 2007,110(3 ) : 587 -593.
  • 4Parkin L, Sharpies K, Hernandez RK, et al. Risk of venousthromboembolism drospirenone or levonorgestrel : nested case -control study based on UK General Practice Research Database[ J].BMJ,2011, 340: d2139.
  • 5Jick SS, Hemades RK. Risk of non - fetal venous thromboembolismin women using oral contraceptives containing drospirenonecompared with women using oral contraceptives containiglevonorgestrel : case - control using United States claims data [ J ].BMJ, 2011,340:d2151.
  • 6Gadducci A, Barsotti C, Cosio S, et al. Smoking habit, immunesuppression,oral contraceptive use,and hormone replacementtherapy use and cervical carcinogenesis : a review of the literature[J]. Gynecol Endocrinol, 2011, 27(8) : 597 -604.
  • 7Sayed GH,Zakherah MS, El - Nashar SA, et al. A randomizedclinical trial of a levonorgestel - releasing intrauterine system andalow 一 dose combined oral contraceptive for fibroid - relatedmenorrhagia[ J]. Int J Gynecol Obsted, 2011, 112(2) : 126 - 130.
  • 8Bahamondes L, Monteiro 一 Dantas, Espejo - Arce X,et al. Aprospective study of the forearm bone density of users ofetonorgestrel — and levonorgestreal - releasing contraceptiveimplants[ J]. Hum Reprod, 2006 , 21(2) ; 466 -470.
  • 9Monteiro - Dantas C, Espejo - Arce X,Lui - Filho, et al. Athree-years longitudinal evaluation of the forearm bone density ofusers of etonogestrel - and levonorgestrel - releasing contraceptiveimplants[ J]. Reprod Health,2007,4:11.
  • 10Pongsatha S, Ekmahachai M, Suntomlimsiri N, et al. Bonemineral density in women using the subdermaJ contraceptiveimplant Implanon for at least 2 years[ J]. Int J Gynaecol Obstet,2010,109(3) : 223 -225.

引证文献6

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部